Novo Nordisk says to market improved insulin in 2013

Dec 23, 2010

Danish pharmaceutical company Novo Nordisk said Thursday it planned to put a new insulin product on the market by 2013 after tests showed advantages to the widely sold diabetes drug Lantus.

"We believe that this ultra long-acting fourth-generation will be a serious competitor to Lantus when it reaches the market in 2013," said Mike Rulis, a spokesman for the company which is a leader in treatments for .

Novo Nordisk on Thursday released results of studies it said showed that its product, Degludec, reduced the risk of dangerous drops in blood sugar levels during the night by 25 percent compared to Lantus, which is manufactured by the French company Sanofi-Aventis.

"Nocturnal hypoglycaemia -- episodes of too low blood sugar during the night -- is a major worry for many people with diabetes," Mads Krogsgaard Thomsen, Novo Nordisk's executive vice president and chief science officer, was quoted as saying in a statement.

According to the World Health Organisation, more than 220 million people worldwide have diabetes, which occurs when the body cannot produce insulin to regulate levels or cannot use natural insulin effectively due to overweight and absence of sufficient exercise.

Explore further: Japan first nation to approve Novartis psoriasis drug

add to favorites email to friend print save as pdf

Related Stories

Impaired fat-burning gene worsens diabetes

Feb 07, 2008

Researchers at the Swedish medical university Karolinska Institutet have in collaboration with researchers from Finland, China, Japan and the US discovered new cellular mechanisms that lead to in insulin resistance in people ...

FDA notes heart events, tumors with Novo drug

Mar 31, 2009

(AP) -- Federal health officials say a potential blockbuster diabetes drug from Novo Nordisk appears to work. But they say questions remain about its effect on the heart and other organs.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

Dec 22, 2014

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.